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The immunosuppressive drug rapamycin has helped to
identify a large signaling network around the target of
rapamycin (TOR) protein that integrates information on
nutrient availability and growth factors to control protein
synthesis and cell size. Studies using rapamycin in animal
models of kidney disease indicate that mTOR deregulation
has a role in glomerular disease, polycystic kidney disease,
and renal cancer. The role of mTOR activation in podocytes
is context dependent, and indirect evidence suggests that
mTOR may have a role in chronic podocyte loss. Several lines
of evidence show that cyst formation in polycystic kidney
disease (PKD) involves mTOR activation and its upstream
regulator TSC. Polycystin 1 regulates mTOR activity through
different pathways, and TSC intersects with the primary
cilium, a crucial cell organelle in the pathogenesis of PKD.
Data from hamartoma syndromes provide clear evidence
that mutation of members of the mTOR network results in
renal cancers. The detailed analysis of renal cell carcinomas
has revealed a positive feedback loop involving VHL and
mTOR. Rapamycin and its derivatives have been approved for
the treatment of advanced renal cancer and are being
investigated for the treatment of PKD. Discrepancies exist
between the effects of rapamycin in animal models and the
clinical experience with patients, precluding the widespread
use of mTOR inhibitors in kidney disease. The details of mTOR
signaling in the kidney need to be clarified to hopefully
develop targeted treatments for renal disease in the future.
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The immunosuppressive drug rapamycin has been pivotal in
defining the TOR (target of rapamycin) pathway. After it was
primarily investigated for its antiproliferative effects, it has
become increasingly clear that the TOR pathway controls cell
and organ size and has wide implications in both physiology
and disease.1 The role of rapamycin has been studied in a
large spectrum of kidney diseases, most notably in diabetic
nephropathy (DN) and polycystic kidney disease (PKD).
Complementation of these studies by exciting molecular data
indicates that beyond proliferation, the TOR pathway has
specific roles in the pathophysiology of these conditions.
Detailed analyses of signaling abnormalities in renal cancer
have pinpointed a crucial role of TOR in this disease, and
derivatives of the TOR inhibitor rapamycin have been
approved for treatment of advanced renal carcinoma. As a
number of excellent up-to-date reviews have been published
on TOR signaling,2–4 the current review will give a brief
overview of the TOR pathway and will focus on recent
advances relevant to the kidney field.
THE INS AND OUTS OF TOR SIGNALING
TOR controls cell mass
TOR was first identified in yeast mutants resistant to the
effects of rapamycin.5 In yeast, two partially redundant TOR
proteins exist. They comprise large serine/threonine kinases
of the phosphoinositide kinase family that function as part
of two multimeric protein complexes, namely TORC1 and
TORC2. In mammals, only one TOR protein (mTOR) of
289 kDa is found.2 mTOR associates with the nonenzymatic
scaffolding proteins Raptor (regulatory-associated protein of
TOR) in mTOR complex 1 (mTORC1) and Rictor (rapamycin-
insensitive companion of mTOR) in mTOR complex 2
(mTORC2) (see Figure 1).1 mTORC1 and mTORC2 are
multiprotein complexes that further include the WD40-
containing protein mLST8 (mammalian lethal with Sec13
protein 8) and the negative regulator Deptor (DEP-domain
containing mTOR-interacting protein).2 In addition,
mTORC1 associates with the inhibitory protein PRAS40
(proline-rich Akt substrate of 40 kDa), which itself is
inhibited by AKT (protein kinase B).4 mTORC2 requires
mSIN1 (mammalian stress-activated protein kinase-interact-
ing protein) for its function. Rapamycin binding to FKBP12
(FK506-binding protein of 12 kDa) acutely inhibits the
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function of mTORC1, but not that of mTORC2, and much
more is known about the function of the rapamycin-sensitive
complex.1,2,4 Activation of mTORC1 most prominently
results in the phosphorylation of two downstream targets,
the ribosomal S6Kinase (S6K) and 4E-BP (eukaryotic
translation-initiation factor 4E-binding protein), which
stimulate ribosome biogenesis and translation to increase
cell mass.6,7 Indeed, TOR and S6K mutant Drosophila are
much smaller than wild-type animals while the cell number is
unaltered.8,9 Another manner by which mTOR regulates cell
mass is by inhibiting autophagy, a physiological starving
mechanism that returns the cell mass through degradation to
the nutrient pool.2
TOR is regulated by different incoming signals
mTORC1 activation is regulated by a complex network of
partially opposing signaling inputs.2 mTORC1 is directly
activated by the Ras-related GTPase Rheb (Ras homolog
enriched in the brain), which associates with mTORC1 in
the perinuclear region on stimulation of RAG (Ras-related
GTP-binding protein) GTPases by amino acids.10 Activation
of mTORC1 by Rheb is repressed by the tuberous sclerosis
complex (TSC) that consists of hamartin (TSC1) and tuberin
(TSC2).11,12 On stimulation by growth factors and insulin
signaling, TSC2 is phosphorylated by AKT, ERK (extra-
cellular signal-regulated kinase 1), or RSK1 (ribosomal S6K)
at specific sites which render the TSC complex inactive and
allow Rheb to activate mTORC1.4 Conversely, during energy
depletion, TSC2 is phosphorylated at a different site by
AMPK (AMP-activated protein kinase), resulting in the
activation of the TSC complex, thereby inhibiting mTORC1
activity. Similarly, TSC2 is phosphorylated and activated by
GSK3 (glycogen synthase kinase 3).13 TSC2 phosphorylation
through GSK3 is inhibited by Wnt (wingless) signals, which
leads to the activation of mTORC1. In addition to indirect
mTORC1 control through the TSC complex and Rheb, direct
inputs exist at the level of the mTORC1 complex. Growth
factor signaling-activated AKT dissociates the inhibitor PRAS40
from mTORC1, resulting in activation of the complex.14–16
Conversely, AMPK signaling directly inhibits mTORC1 through
the phosphorylation of Raptor.17 How mTORC2 is activated










































Figure 1 |The mTOR pathway. The mTOR protein is part of two protein complexes: mTORC1 and mTORC2. mTORC1 is activated by growth
factor signaling and amino acids to phosphorylate 4E-BP and S6K, resulting in ribosome biogenesis and protein translation, and to
inhibit autophagy. mTORC1 is negatively regulated by the TSC complex. Activating proteins are shown in green, inhibiting proteins in red.
mTORC2 is activated through unknown mechanisms to phosphorylate AKT and to regulate the actin cytoskeleton through PKC. For details
see the main text. aa, amino acid; AKT, protein kinase B; AMPK, AMP-activated protein kinase; Deptor, DEP-domain containing mTOR-
interacting protein; 4E-BP, eukaryotic translation-initiation factor 4E-binding protein; ERK1/2, extracellular signal-regulated kinase 1/2;
FKBP12, FK506-binding protein of 12 kDa; FoxO, forkhead box O1; GSK3, glycogen synthase kinase 3; LKB1, serine threonine kinase 11;
mLST8, mammalian lethal with Sec13 protein 8; mSIN1, mammalian stress-activated protein kinase-interacting protein; mTORC, mammalian
target of rapamycin complex; PI3K, phosphoinositide-3 kinase; PKC, protein kinase C; PRAS40, praline-rich Akt substrate of 40 kDa;
PTEN, phosphatase and tensin homolog deleted on chromosome 10; RAG, Ras-related GTP-binding protein; Raptor, regulatory-associated
protein of TOR; Rheb, Ras homolog enriched in the brain; Rictor, rapamycin-insensitive companion of mTOR; RSK1, ribosomal S6 kinase;
S6K, p 70 ribosomal S6 kinase; TSC, tuberous sclerosis complex; TSC1, hamartin; TSC2, tuberin; Wnt, wingless.
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site.2 Ablation of this function leads to the activation of FoxO
(forkhead box O1) transcription factors and transcription
of stress resistance and apoptosis genes. In addition, mTORC2
phosphorylates conventional and atypical forms of protein
kinase C and is involved in the organization of the actin
cytoskeleton.2
mTOR regulates autophagy
Cellular size is controlled through a balance between cell
growth and autophagy. Autophagy refers to the process of
self-degradation of cellular components in which proteins
and organelles are sequestered and modified within cytosolic
double-membrane vesicles, the autophagosomes, and subseq-
uently delivered to the lysosome.18 How mTOR regulates
autophagy is unknown but induction of autophagy by
mTORC1 inhibition is largely responsible for the potent
effect of starvation on cell size, and rapamycin induces
autophagy in a wide variety of cell types and species by
inhibiting the activity of mTORC1.19 Besides its role in
starving, autophagy is an important homeostatic and quality
control mechanism that maintains cellular integrity and has
been shown to be essential for long-lived post-mitotic cells,
such as neurons18 and glomerular podocytes.20 In addition to
the removal of intracellular aggregates and damaged
organelles, autophagy facilitates antigen presentation, pro-
tects against aging, and prevents necrosis, giving it a key role
in preventing diseases, such as cancer, neurodegeneration,
cardiomyopathy, diabetes, liver disease, autoimmune dis-
eases, and infections.21 In the kidney, autophagy has been
shown to protect against tubular ischemia–reperfusion
injury,22 to regulate podocyte homeostasis,20 and to mediate
caloric restriction-induced protection of kidney aging.23 In
addition to the function of autophagy as a survival
mechanism, the autophagy protein machinery has a role in
programmed cell death.24 Although the role of mTORC1 in
this process has not been established, it is clear that cell
survival and cell death through autophagy need to be
considered when interpreting the effects of rapamycin in
tissue disease models.
mTOR SIGNALING IN GLOMERULAR DISEASE
The effect of rapamycin on DN
The wide availability of rapamycin as a specific mTORC1
inhibitor and its use in animal models of kidney disease has
aided our recognition that mTOR signaling has a role in the
pathophysiology of different nephropathies. In particular,
results from models of DN indicate that inhibition of the
mTOR pathway with rapamycin may have beneficial effects
on the progression of this disease in animals (see Table 1).25–32
DN is the leading cause of end-stage renal disease33 and is
characterized by progressive albuminuria and the gradual
decline of glomerular filtration rate (GFR). This process is
morphologically characterized by hypertrophy of the glomer-
ulus, podocyte loss leading to glomerular sclerosis and,
ultimately, progressive tubulointerstitial fibrosis.34 Multiple
signaling abnormalities that contribute to the clinical and
pathologic hallmarks of DN have been identified; however,
no comprehensive molecular basis for DN has been
established.35
Podocyte damage in DN may be due to mTOR deregulation
It has long been known that irreversible structural changes in
the kidneys of diabetic subjects are preceded by hypertrophy
of the glomerulus with enlargement of glomerular cells,36 and
more recent evidence has identified hypertrophic podocytes
as a prominent early feature of DN.37 These findings point
toward the possibility of altered mTOR signaling, as cell mass
is essentially controlled through the mTOR pathway1 and
as activation of mTOR is involved in other hypertrophic
responses, such as cardiac hypertrophy.38 However, to date,
in vivo evidence of increased mTORC1 activity in podocytes
of diabetic animals is still lacking. What could be the stim-
ulus that activates mTOR in podocytes and other renal
cells in diabetes? mTOR is activated by both growth factors
and nutrients, such as glucose and amino acids.1,10,31 As DN
occurs in both type 1 (hyperglycemia) and type 2 (hyper-
glycemia plus hyperinsulinemia) diabetes, hyperglycemia
would be expected to activate the mTOR pathway indepen-
dently of growth factors.39 Hyperglycemia may act through
Table 1 | Implications of mTORC1 signaling on diabetic nephropathy in animal studies
Experimental manipulation
of the mTOR pathway
Studied affected
kidney tissue Effects on DN Reference
S6 kinase 1 knockout (mice) Kidney Renal hypertrophy k Chen et al.25
Sirolimus (rats) Glomerulus Glomerular hypertrophy k podocyte loss k
TGF-b1/2 increase k VEGF increase k
Wittmann et al.29
Rapamycin (mice) Glomerulus Glomerular hypertrophy k mesangial matrix expansion k Mori et al.27
Rapamycin (mice) Proximal tubule,
glomerulus
Renal hypertrophyk laminin-b1k Sataranatarajan et al.32
Rapamycin (rats) Glomerulus TGF-b1 mRNA increase k VEGF mRNA increase k Yang et al.30
Metformin, AICAR: AMPK
activation (rats)
Kidney Renal hypertrophy k Lee et al.31
Sirolimus (rats) Glomerulus GBM thickness increase k mesangial matrix expansion k Lloberas et al.26
Rapamycin (mice) Kidney Renal hypertrophy k Sakaguchi et al.28
Warfarin: Gas6 inactivation (rats);
Gas6 knockout (mice)
Glomerulus Glomerular hypertrophy k mesangial matrix expansion k Nagai et al.,108
Arai et al.109
Abbreviations: AICAR, 5-aminoimidazole-4-carboxamide-1b-riboside; AMPK, AMP-activated protein kinase; DN, diabetic nephropathy; GBM, glomerular basement membrane;
mTORC, mammalian target of rapamycin complex; TGF-b1/2, transforming growth factor-b1/2; VEGF, vascular endothelial growth factor.
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AMPK which acts under physiological conditions as the
downstream component of a kinase cascade that senses
cellular energy charge40 and is inhibited in type 1 and type 2
diabetic kidneys.31 As AMPK is an essential mTOR
suppressor, inhibition of AMPK activity in the presence of
hyperglycemia could lead to mTOR activation.40 In support
of this hypothesis, the AMPK activator metformin sup-
pressed mTOR activity in cultured glomerular epithelial
cells and ameliorated renal hypertrophy in type 1 diabetic
animals.31 In patients with DN and a GFR below
60ml/min, metformin is contraindicated because of the risk
of lactic acidosis. However, it is astounding that 450 years
after the clinical introduction of metformin,41 its effect on
early DN has not been rigorously studied.42
Podocyte number per glomerulus is a strong predictor of
renal disease progression in diabetic individuals.43 It is
conceivable that mTOR hyperactivation in the presence of
hyperglycemia mediates a sustained hypertrophic stimulus in
the podocyte that might eventually lead to podocyte
degeneration and to the development of glomerulosclerosis
and proteinuria. Support of this concept comes from
podocyte-specific Atg5 knockout mice that are deficient in
autophagy.20 These animals display a phenotype of progres-
sive podocyte loss and glomerulosclerosis, suggesting that
autophagy is important for the homeostasis of podocytes. As
autophagy is negatively regulated by mTORC1 activity,2 it is
possible that mTOR stimulation in the diabetic state damages
podocytes by inhibiting autophagy.
Rapamycin affects many features of DN: findings and caveats
In addition to preventing glomerular hypertrophy in the early
stages of DN, rapamycin seems to ameliorate mesangial
expansion, glomerular basement membrane thickening, and
renal macrophage recruitment in type 1 diabetic rats, and to
prevent proteinuria.30 mTOR is ubiquitously expressed, and
it is not surprising that aside from its role in glomerular
hypertrophy, mTOR activation seems to contribute to
other typical features of DN (see Table 1).39,44 Among them
are: (1) mTOR-dependent induction of the synthesis of
matrix proteins45 that contribute to basement membrane
thickening and the accumulation of mesangial matrix
characteristic of DN;46,47 (2) mTOR-dependent stimulation
of fibroblast proliferation and the increased expression of
profibrotic cytokines, such as transforming growth factor-b1
and connective tissue growth factor,26,30 which mediate the
tubulointerstitial changes associated with DN;34 (3) mTOR-
dependent epithelial-to-mesenchymal transition48 that might
contribute to tubulointerstitial fibrosis in DN; (4) mTOR-
dependent influx of lymphocytes and macrophages and the
release of proinflammatory cytokines that might support the
inflammatory process in DN; and46,47 (5) mTOR-dependent
proximal tubular dysfunction in the remnant kidney
model.49 However, caution is required in the interpretation
of mTOR’s role in these different aspects of DN as most
current insights on mTOR signaling in the pathophysiology
of this disease are derived from pharmacological inhibition of
the pathway by rapamycin, which affects both resident
and infiltrating cells in the kidney, making it impossible to
differentiate the relative role of mTOR activation between
different cell types. Furthermore, off-target effects have been
described with longstanding application of rapamycin, most
notably the inhibition of mTORC2.50 Therefore, tissue-
specific analysis of mTOR signaling will be required for an
in-depth understanding of the functional role of mTOR in
DN and other glomerular diseases.
Glomerular effects of rapamycin: animal models versus the
patient experience
Apart from DN, recent studies have suggested that mTOR
inhibition delays or reverses glomerular disease and renal
fibrosis in other renal disease models, for instance, focal
segmental glomerulosclerosis,51 progressive membranous
nephropathy in rats,52,53 renal obstruction after ureteral
ligation,48,54 and reduced renal mass.55 In contrast to the
situation in DN, less information exists on the specific input
signals that lead to the upregulation of mTOR signaling, but
oxidative stress and growth factor signaling are the likely
candidates.
An interesting conundrum exists regarding the effects of
rapamycin in glomerular disease. Although several studies
have unambiguously demonstrated that general inhibition of
mTORC1 by rapamycin is protective in animal models of
glomerular disease, in human patients, rapamycin frequently
causes a dramatic increase in proteinuria, which is often not
reversible after discontinuation of the drug.56 Chronic
allograft nephropathy involving glomerular changes poses
patients at increased risk for this complication.57 However, in
patients receiving de novo rapamycin after renal transplanta-
tion, increased apoptosis of podocytes has also been
observed,58 and some patients developed focal segmental
glomerulosclerosis.57 To address this discrepancy, the effects
of rapamycin were examined in a toxic model of glomerular
damage and compared with a model of chronic hyperfiltra-
tion.59 Rapamycin increased proteinuria and worsened foot
process effacement in puromycin-treated rats but had
protective effects in animals treated by renal mass reduction.
Interestingly, rapamycin treatment increased glomerular
apoptosis in the puromycin model, whereas apoptosis was
less in hyperfiltration, suggesting that the role of rapamycin is
context dependent. It is noteworthy that in a different study
of 5/6 nephrectomized rats, rapamycin increased proteinuria
and worsened disease progression.60 Rapamycin increased the
expression of the slit diaphragm protein nephrin in the
glomerular hyperfiltration model.59 However, in cultured
podocytes, rapamycin decreased nephrin expression.61 These
discrepancies strongly indicate that the role of mTOR
signaling in glomerular disease is heterogeneous. Detailed
analyses of mTOR-associated regulatory events in glomer-
ulopathies and podocytes are required to understand the
complex role of this pathway in glomerular disease and to
solve the discrepancies between the observations in humans
and rodent models. In light of the clinical experience in renal
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transplant recipients and patients with advanced glomer-
ular disease,62 a better understanding of the role of mTOR
signaling in glomerulopathies is necessary, and possibly
new mTOR-modifying drugs must become available before
intervention studies targeting the mTOR pathway are
designed for the treatment of glomerular disease.
mTOR signaling in PKD
The finding that mTOR inhibitors reduce cyst formation has
sparked a profound interest in the role of mTOR signaling
in PKD. Two studies in the Han:SPRD rat model of PKD
demonstrated that rapamycin treatment led to decreased cyst
and kidney volume and improved renal function compared
with control animals.63,64 These results suggested that rapamy-
cin has a specific effect on cyst growth. Similar findings were
reproduced in PKD animal models of different genetic back-
grounds including the orpk mouse, the bpk mouse that is
reminiscent of autosomal recessive polycystic kidney disease,65
and importantly, a conditional Pkd1-deficient mouse,66 thus
providing proof of principle in an analogous model of human
ADPKD. Phosphorylation of the mTORC1 downstream target
S6K was increased in lysates from cystic kidneys64 and cyst
epithelia on kidney sections obtained from patients with
ADPKD stained strongly for phosphorylated S6K,65 suggesting
that increased mTORC1 activity contributes to the pathogenesis
of ADPKD.
Loss of TSC function activates mTORC1 and causes cyst
formation
Tuberous sclerosis proteins provide a direct line of evidence
that activation of the mTOR pathway results in cyst
formation. Patients with tuberous sclerosis carry a hetero-
zygous mutation in TSC1 or TSC2 genes.67 The encoding
proteins hamartin and tuberin act in a complex as the central
inhibitor of mTORC1 activity.2 Besides the formation of
benign tumors in the brain, the kidney, and the skin,
tuberous sclerosis is characterized by the development of
kidney cysts.67 Mice with kidney-specific inactivation of both
alleles of Tsc1 revealed activation of the mTORC1 down-
stream targets 4E-BP1 and S6K and formed massive cysts in
the kidney that were responsive to rapamycin treatment.68
Although these data strongly suggest that mTORC1 activa-
tion is sufficient to cause cyst formation, genetic evidence
showing that mTORC1 is necessary for cystogenesis is still
lacking. This is a point of particular concern, as several
studies have found evidence of mTORC1 activity in only as
few as 40% of cysts69–71 and deserves further study.
Polycystin 1 cooperates with TSC to inhibit the mTOR
pathway
How is mTORC1 activated in the pathogenesis of cyst
formation? Interestingly, the kidney-specific deletion of
PTEN (phosphatase and tensin homolog), a negative
regulator of growth factor-mediated activation of AKT, did
not result in cyst formation despite moderate activation of
mTORC1 activity as shown by increases in p-S6K levels.68,72
These results exclude growth factor signaling as a major
upstream regulator of mTOR signaling in tubular epithelial
cells. Patients with the contiguous gene syndrome consisting
of a deletion of PKD1 and TSC2 genes have a severe form of
early-onset PKD,67 suggesting that both gene products act in
the same pathway. This is supported by molecular data (see
Figure 2). An early study in the Eker rat that lacks a copy of
the TSC2 gene demonstrated that trafficking of polycystin 1
(PC1) to the lateral membrane is impaired.73 Another study
found that the overexpressed intracellular tail of PC1
interacted with mTOR and colocalized with the TSC2
product tuberin.65 In a different approach, the role of PC1
on mTORC1 activity was analyzed in PC1-overexpressing
cells and PKD1/ cells.74 On the basis of the finding that
cyst lining epithelial cells are larger than tubular cells75 and
the fact that mTOR is the main controller of cell size,1
Distefano et al.74 analyzed cell volumes and demonstrated
that overexpression of PC1 resulted in smaller cells and that
PKD1/ cells were larger than PKD1þ /þ cells, suggesting
an inverse relationship between PKD1 and mTORC1 activity.
The cell size decrease was accompanied by reduced
phosphorylation of the mTORC1 downstream targets
4E-BP1 and S6K and was independent of AKT. Interestingly,
overexpression of PC1 was accompanied by decreased ERK
phosphorylation, and a careful analysis suggested that
mTORC1 and cell-size regulation through PC1 required the















Figure 2 |Model of mTORC1 regulation in epithelial cells.
(1) Under physiological conditions, polycystin 1 (PC1) blocks ERK-
dependent inhibition of TSC2. In the absence of PC1, ERK activates
mTORC1. (2) TSC2 interacts with PC1 and facilitates trafficking
of PC1 to the plasma membrane. (3) PC1 interacts with mTOR.
(4) The TSC complex regulates ciliary length. (5) In polycystic
kidney disease, localized ischemia may contribute to mTORC1
activation. ERK1/2, extracellular signal-regulated kinase 1/2;
mTORC, mammalian target of rapamycin complex; TSC, tuberous
sclerosis complex; TSC1, hamartin; TSC2, tuberin.
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These data were recently confirmed in a second study,76
whereas another study failed to find activation of the mTOR
pathway in PKD1/ mouse embryonic fibroblasts.70 In
summary, cumulative evidence suggests that PC1 suppresses
mTOR activity and that other as yet unidentified pathways
are involved in this regulation, which may explain cell-
specific differences.
The primary cilium, a crucial organelle in the pathogenesis
of PKD, intersects with TSC
The pathophysiology of PKD is rooted in the dysfunction of the
primary cilia, filiform organelles situated at the apical membrane
of tubular cells that act as flow sensors and are believed to
regulate epithelial cell polarity.77–80 Several studies have found a
role of TSC proteins in the regulation of ciliary length.69,70,81
TSC1/ or TSC2/ MEFs had up to 30% longer cilia com-
pared with control mouse embryonic fibroblasts.70 Interestingly,
this phenotype was unaltered by treatment with rapamycin,
suggesting that this effect is mTORC1 independent. A different
study analyzed the length of the cilia in heterozygous TSC1þ /
or TSC2þ / mice and found small but significant differences in
precystic tubules.69 However, although the cilia were roughly
twice as long in the cystic epithelia, they were shorter in precystic
tubules compared with wild-type animals, suggesting that there
may be a difference between the homozygous and heterozygous
phenotypes. A third study investigated the cilia in TSC1
morphant zebrafish.81 Targeting TSC1 by morpholino antisense
oligonucleotides resulted in cyst formation and activation of
mTOR signaling. Similar to homozygous TSC knockout mice,
the cilia in the pronephric ducts of TSC morphants were on
average 65% longer than in wild-type embryos. It has been
shown that the biophysical characteristics of the cilia vary with
cilia length;82 however, direct evidence of altered flow sensing in
TSC-deficient cells is lacking. To date, no evidence exists that the
cilia themselves regulate mTOR signaling.
Does ischemia have a role?
A number of studies have shown that inactivation of the cilia
or PKD genes in adult mice per se does not cause cyst
formation and that polarity defects and cyst formation occur
after ischemic injury.79,83–85 Although acute kidney injury
due to global ischemia–reperfusion injury is unlikely to occur
during the natural course of PKD, the ischemia marker
kidney injury molecule 1 is upregulated in tubular cells
adjacent to cysts,86 suggesting that ischemia occurs on a
cellular level. mTOR signaling seems to have a role in renal
repair after ischemia–reperfusion injury as suggested by
increased phosphorylation of S6K in postischemic kidneys
and a recovery delay after rapamycin treatment.87 It remains
to be shown whether ischemia is a precipitating event for
inducing activation of the mTOR pathway in PKD.
The role of mTOR signaling in compensatory nephron
hypertrophy
Loss of renal mass results in compensatory hypertrophy of
the remaining functional nephrons. mTOR signaling is
known to mediate adaptive muscle hypertrophy in the
heart;38 therefore, the question arises whether it has a role in
glomerular hyperfiltration. The analysis of uni-nephrecto-
mized mice demonstrates that the mTORC1 target S6K is
activated in the remaining kidney and that hypertrophy is
prevented by rapamycin treatment.25 Importantly, genetic
inactivation of S6K also largely ablates hypertrophy in the
remnant kidney.25 In the clinical setting, it would therefore be
expected that pharmacological mTOR inhibition antagonizes
the compensation mechanism and worsens GFR in the short
term in patients with compensatory nephron hypertrophy. In
this respect, interesting data exist from a conversion study in
which renal transplant patients were switched from calci-
neurin to mTOR inhibitors.88 Although several studies have
found an acute increase in GFR after early conversion to
mTOR inhibitors,89,90 likely due to glomerular hemodynamic
effects from discontinuing calcineurin inhibitors, a controlled
prospective trial of renal transplant patients who were
randomly converted after a mean of 39 months after
transplantation found a GFR benefit only in patients with a
GFR440ml/min.88 On the other hand, patients with a GFR
of 20–40ml/min had no GFR increase after conversion
compared with patients maintained on calcineurin inhibi-
tors. Similarly, a series of patients with advanced glomerular
disease mostly developed acute renal failure when treated
with rapamycin.62 Loss of GFR through mTOR inhibition
may also explain some findings in patients with ADPKD
treated with everolimus91 (see below). As glomerular
hyperfiltration is deemed detrimental in the long term,
clinical trials need to be designed with adequate follow-up to
detect long-term benefits in renal function.
Clinical trials with mTOR inhibitors in ADPKD
Three placebo-controlled trials have recently explored the
effects of mTOR inhibition in patients with ADPKD;
curiously, they report different outcomes.
In a study published by Perico et al.,92 the investigators
performed a randomized crossover trial (The Sirolimus
Treatment in Patients with Autosomal Dominant Polycystic
Kidney Disease: Renal Efficacy and Safety (SIRENA) study),
comparing the effects of a 6-month therapy with sirolimus
(target level: 5–10 ng/ml) with 6 months of conventional
therapy on kidney volume in 15 patients with ADPKD (age:
39.1 years, estimated GFR (eGFR): 76.5ml/min per 1.73m2,
total kidney volume (TKV): 1874ml). TKV increased by 46ml
during sirolimus and by 70ml during conventional treatment;
the difference between the two treatment modalities was
statistically not significant (P¼ 0.45). Cyst volume increased
by 4ml during sirolimus and by 55ml during conventional
treatment; this difference was statistically significant
(P¼ 0.023). Conversely, renal parenchyma increased by
26ml in patients treated with sirolimus, but remained stable
(2ml) during conventional treatment (P¼ 0.008). No
serious adverse events occurred during therapy with sirolimus.
The authors concluded that sirolimus inhibits cyst growth and
increases parenchymal volumes in patients with ADPKD.
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In contrast to the SIRENA study, the SWISS ADPKD
study did not detect any effects of sirolimus on TKV in an
open-label single-center trial.93 Serra et al. randomized 100
patients to receive either sirolimus (age: 31 years, eGFR:
92ml/min per 1.73m2, TKV: 907ml) or conventional care
(age: 32 years, eGFR 91ml/min per 1.73m2, TKV: 1003ml).
Over a treatment period of 18 months, TKV increased by
99ml in the sirolimus group and by 97ml in the placebo
group. The eGFR remained basically unchanged in the
sirolimus group (þ 0.2ml/min per 1.73m2), but decreased
slightly in the placebo group (3.5ml/min per 1.73m2)
(P¼ 0.07). Adverse events, in particular mucositis, diarrhea,
and acne, were more common in the sirolimus group;
however, infection rates were similar in both groups.
A third trial studied the mTOR inhibitor everolimus in
ADPKD patients with more advanced disease,91 and enrolled
patients with either an eGFR between 30 and 89ml/min
per 1.73m2 or a single kidney volume X1000ml. In this
multicenter, double-blind, placebo-controlled trial, 433
patients with ADPKD (mean age: 44–45 years, eGFR
53–56ml/min per 1.73m2, TKV 1911–2028ml) were ran-
domly assigned to receive everolimus (target level: 3–8 ng/ml)
or placebo. TKV increased by 102ml in the everolimus group
versus 157ml in the placebo group after 1 year (P¼ 0.02) and
by 230 and 301ml after 2 years (P¼ 0.06). Parenchymal
volume increased by 26ml in the everolimus group and by
62ml in the placebo group after 1 year (P¼ 0.003) and by
56 and 93ml after 2 years (P¼ 0.11). The mean decrease in
the eGFR after 24 months was 8.9ml/min per 1.73m2 in
the everolimus group versus 7.7ml/min in the placebo group
(P¼ 0.15). As in the Swiss ADPKD study, drug-specific
adverse events were more common in the everolimus group,
whereas the rate of infection was similar in both groups.
Thus, two trials (SIRENA and everolimus in ADPKD)91,92
report that mTOR inhibition slows the increase in TKV.
The changes in TKV per year in these two trials were
B150ml/year in the placebo/conventional treatment group,
and were comparable with the TKV changes reported by the
Consortium for Radiologic Imaging Studies of Polycystic
Kidney Disease consortium for the corresponding subgroup
(patients 430 years with at baseline TKV 41500ml).94
Roughly, treatment with mTOR inhibitors reduced the
increase in TKV by one-third. Both trials enrolled patients
with relatively large kidneys (combined volume of B2 l). In
contrast, the mean TKV of ADPKD patients enrolled in the
SWISS trial was considerably smaller (approximately one
liter).93 Thus, advanced disease with large kidneys seems to
be necessary to detect volumetric changes by computer
tomography (used in the SIRENA study) or magnetic
resonance imaging (used in the SWISS/everolimus trial)
within a relatively short period of time (o24 months). The
discrepancy between changes in parenchymal volumes (an
increase in the SIRENA study versus a decrease in the
everolimus trial) is difficult to explain, but may be the result
of different imaging methods. The decrease in parenchymal
volume (particularly occurring during the first year) could
explain the more pronounced decline in renal function
observed in everolimus- versus placebo-treated patients after
the first 12 months (DeGFR 2.2ml/min per 1.73m2;
P¼ 0.004).91 Interestingly, no difference in renal function
was observed after 24 months, suggesting that mTOR
inhibition reverses nephron hypertrophy without affecting
long-term renal function. The complex effects of mTOR
inhibitors on renal function are underlined by the SWISS
trial: in patients with fairly preserved renal function,
treatment with sirolimus seemed to stabilize renal function,
whereas placebo-treated patients experienced a steady decline
in eGFR; at the end of the 18-month treatment period, the
difference in eGFR almost reached statistical significance
(P¼ 0.07).93 Clearly, longer treatment periods are required to
determine the effects of mTOR inhibitors on renal function
in ADPKD. Potential effects of mTOR inhibition on nephron
hypertrophy may also complicate the interpretation of renal
function in other settings, including renal transplantation:88
when comparing mTOR inhibition with calcineurin inhibi-
tors, the potential benefits of mTOR inhibitors may be
obscured by inhibition or reversal of nephron hypertrophy
during the first 24 months, although inhibition of hyperfil-
tration may exert beneficial effects on the long-term
outcome. Another interesting lesson learned from these trials
is the lack of correlation between TKV and eGFR: although
cyst and kidney growth correlate with progressive deteriora-
tion in renal function,94 slowing kidney growth and volume
with everolimus did not necessarily translate into improved
renal function, at least not within a 2-year observation
period. Although changes in TKV and kidney compartments
may help to understand the renal physiology of ADPKD
patients in response to therapeutic approaches, their utility as
a surrogate parameter for renal function may be limited.
Inhibition of mTOR activity is associated with a broad range
of side effects—some of which seem to be ameliorated by the
concurrent immunosuppression used in transplant patients.
Upregulation of mTOR activity clearly contributes to cyst
growth in human ADPKD and in animal models of recessive
cystic kidney disease. Thus, it will be important to continue
exploring the potential of mTOR inhibition in ADPKD,
hopefully with a second generation of mTOR inhibitors that
display fewer side effects.
mTOR signaling in renal cancer
It is increasingly recognized that mTOR signaling has an
important role in cancer.95 The cumulative knowledge based
on the deregulation of mTOR signaling is greatest for renal
cancer. As a large number of reviews have addressed this
topic in great detail,96–98 it will be discussed only briefly in
this review.
Inherited hamartoma syndromes
The first hint of a connection between mTOR signaling and
renal cancer comes from the inherited hamartoma syn-
dromes.67,99,100 Interestingly, several of these hereditary tumor
syndromes have mutations in mTOR-associated proteins.
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Patients with tuberous sclerosis lack TSC-mediated suppression
of mTORC1 activity and develop benign renal angiomyolipo-
mas and renal cell carcinomas.67 The Peutz–Jeghers syndrome is
caused by a mutation in the tumor-suppressor gene LKB1,
which functions as an activator of the mTOR suppressor
AMPK.99 Affected patients develop tumors mostly in the
gastrointestinal tract but in addition have an increased
incidence of carcinomas, including renal cancer.101 The BHD
(Birt–Hogg–Dube´) disease is an autosomal dominant
hamartoma syndrome that is characterized by renal cancer,
spontaneous pneumothorax, and hair follicle tumors.100 It is
caused by a mutation in the FLCN gene coding for folli-
culin, a 579 amino-acid protein of unknown function that
is believed to act as a tumor suppressor. Two folliculin-
interacting proteins, namely FNIP1 and FNIP2, interact with
AMPK. However, in yeast, folliculin acted opposite to TSC1
and TSC2 and downregulated TOR signaling.100 In mouse
models, the situation is less clear: one study found decreased
mTOR phosphorylation in early renal tumors in hetero-
zygous BHDþ / mice,102 whereas a second study found
increased mTOR activity in malignant renal tumors from
BHDþ / mice generated by a different genetic approach.103
In addition, this study found evidence of increased mTORC1
activity in renal cell carcinomas from BHD patients,
indicating that mTOR may be upregulated at least in
advanced cancers.
A positive feedback loop exists between VHL and mTOR
The most common cancer syndrome to involve the kidney is
Von Hippel Lindau (VHL) disease,96 which leads to clear cell
carcinomas in the kidney. So far, no direct interaction has
been established between the VHL protein and members of
the mTOR signaling cascade. Nevertheless, mTORC1 is
activated in VHL-derived renal cancers indirectly.96 VHL-
deficient cells fail to degrade the transcriptional activator
hypoxia-inducible factor 1-a, which leads to increased
transcription of several target genes, including vascular
endothelial growth factor. Stimulation of the vascular
endothelial growth factor receptor by its ligand activates
the PI3K–AKT pathway and thus mTORC1. In turn, mTOR
signaling activates the transcription of hypoxia-inducible
factor 1-a and is thus part of a positive feedback loop in this
disease.96 Activation of the mTOR pathway in malignant
renal tumors is highly relevant beyond the field of inherited
cancer syndromes as it has been recognized that sponta-
neously occurring renal cell carcinomas not only have a high
frequency of mutations in the VHL gene (70%) but also in
any of the other genes described above.98 Furthermore, in
addition to mutations in proteins of the mTOR pathway and
hypoxia-inducible factor 1-a-mediated mTOR activation,
hypoxia itself is able to induce mTORC1 through several
mechanisms.104
mTOR as a therapeutic target in renal cancer
Renal cancer that is not amenable to surgical resection has
been difficult to treat and confers a poor prognosis for
survival.96 On the basis of the increasing knowledge of signal
transduction abnormalities in renal cancers, a number of
novel targeted therapies have been studied in recent years in
patients with disseminated renal cell carcinomas.97 Apart
from mTOR inhibitors, they include tyrosine kinase
inhibitors and vascular endothelial growth factor receptor
blockers. The use of temsirolimus and everolimus, which
are derivatives of rapamycin, in prospective intervention
trials has proven effective in prolonging progression-free
survival.96 Disappointingly however, the absolute amount of
progression-free survival has been measured in o6 months,
suggesting that the tumors may acquire resistance against
these drugs.105 Emerging molecular insights into the action of
rapamycin indicate that this drug is more heterogeneous in
its mTOR-blocking properties than previously anticipated.106
First, long-term administration of rapamycin blocks
mTORC2 in addition to mTORC1,50 which may suggest that
other, previously unknown, off-target effects exist for this
drug. Second, rapamycin blocks the phosphorylation of S6K
far more efficiently than that of its second downstream target
4E-BP1, indicating a certain degree of specificity for selective
mTORC1 functions.106 A point of particular concern is the
possibility, that selective interruption of the negative feed-
back loop through S6K, PI3K, and AKT may leave mTORC1
downstream targets hyperactivated that are not inhibited by
rapamycin.106 In this respect, it is exciting that new drugs are
being developed which target the mTOR pathway at different
locations,107 opening up the opportunity to gain further
molecular insights and possible new treatments.
CONCLUDING REMARKS
TOR signaling is a rapidly developing field with exciting
prospects for the understanding of disease and the potential
for novel treatments. It has become clear that mTOR
deregulation has an important role in glomerular disease,
PKD, and renal cancer. Current evidence suggests that the
effects of mTOR deregulation are context dependent and cell
type specific. Future studies using genetic and molecular
manipulation, as well as novel mTOR-modifying compounds
will dissect the intricacies of mTOR deregulation in different
kidney diseases. The convergence of knowledge about the vast
mTOR signaling network with details from the pathophysio-
logy of the kidney will hopefully help to develop targeted
therapies for specific kidney diseases in the future.
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